Literature DB >> 30497554

Step-by-Step Approach to Management of Type II Endoleaks.

Yolanda Bryce1, Cuong Ken Lam2, Suvranu Ganguli3, Brian J Schiro4, Kyle Cooper5, Michael Cline5, Rahmi Oklu6, Geogy Vatakencherry2, Constantino S Peña4, Ripal T Gandhi7.   

Abstract

Seventy-five percent of abdominal aortic aneurysms are now treated by endovascular aneurysm repair (EVAR) rather than open repair, given the decreased periprocedural mortality, complications, and length of hospital stay for EVAR compared to the surgical counterpart. An endoleak is a potential complication after EVAR, characterized by continued perfusion of the aneurysm sac after stent graft placement. Type II endoleak is the most common endoleak, and often has a benign course with spontaneous resolution, occurring in the first 6 months after repair. However, these type II endoleaks may result in pressurization of the aneurysm sac and potentially sac rupture. They occur from retrograde collateral blood flow into the aneurysm sac, typically from a lumbar artery or the inferior mesenteric artery. Alternative sources include accessory renal, gonadal, median sacral arteries, and the internal iliac artery. We will discuss our protocol for post-EVAR imaging surveillance and potential type II endoleak treatment strategies, including transarterial, translumbar, transcaval, and perigraft approaches, as well as open surgery.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  endoleak; endovascular aneurysm repair; translumbar embolization; type II endoleak

Mesh:

Substances:

Year:  2018        PMID: 30497554     DOI: 10.1053/j.tvir.2018.06.009

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  1 in total

1.  Direct percutaneous embolization of aneurysm sac: a safe and effective procedure to treat post-EVAR type II endoleaks.

Authors:  Fabrizio Fanelli; Alessandro Cannavale; Emiliano Chisci; Michele Citone; Gian Marco Falcone; Stefano Michelagnoli; Vittorio Miele
Journal:  Radiol Med       Date:  2020-07-13       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.